Missions and tasks
Board of Pharmaceutical Practice (BPP) raises professional standards of pharmacy practice through its activities. The BPP represents the interests of all aspects of the practice of the profession of pharmacy throughout the whole world, regardless of any national or local issues.
The board handles all professional aspects of FIP’s activities and facilitates collaboration between sections.
The development of the profession in all its many facets is encouraged.
Good communication between pharmaceutical practitioners, pharmaceutical scientists and other health care providers is strongly promoted. The ultimate objective is to unify the profession and, as a result, bring about an increase in the standards of health care for the benefit of patients.
The BPP, with these ends in mind, endeavours to:
- Raise professional standards
- Promote safe and effective use of medicines
- Advance pharmacy education and develop and expand continuing education
- Encourage research into all fields of pharmaceutical practice
- Recognise and reward excellence in pharmaceutical practice
- Expand the services, practice models, influence and role of the pharmacist
- Increase, strengthen and expand the functions of the various sections of FIP
- Increase membership and thus influence the activities of FIP on a worldwide basis
The board’s main tasks are to:
- Prepare the professional programmes for the World Congress of Pharmacy and Pharmaceutical Sciences and, where applicable, other conferences of FIP which are professional in nature;
- Maintain contact with the relevant interested parties and assist in the coordination of professional activities of the sections;
- Coordinate the professional activities of FIP in relation with other professional organisations;
- Formulate policy recommendations and establish strategic directions and priorities within the stated mission of the board;
- Set up working groups where the subject matter is outside the responsibility of any of the sections or covers the interest of more than one section
In 2017, the BPP published “Pharmacy
Structure of the board
The BPP comprises:
- Executive committee
- Vice Presidents nominated by the BPP
- Section representatives
- Expert members
The Board of Pharmaceutical Practice, March 2019
BPP Executive Committee
- Chair (2018-2022): Mr Paul Sinclair
- FIP Professional Secretary (2017-2021): Ms Ema Paulino
- Immediate Past Chair (2018-2020): Mr Dominique Jordan
- Elected Member (2016-2020): Prof. Parisa Aslani
- Elected Member (2018-2022): Mr Ulf Janzon
- FIP Scientific Secretary (2019-2023): Prof. Giovanni Pauletti
- and as an ex officio member, FIP CEO: Dr Catherine Duggan
Vice Presidents nominated by the BPP
- FIP Vice President: Ms Eeva K. Teräsalmi (2016-2020)
The sections of the BPP represent various professional groups within the scope of pharmacy practice. The President and Secretary of each section are the official representatives on the BPP. Sections with more than 500 members (i.e. Community Pharmacy Section and Hospital Pharmacy Section) have a third representative.
The expert members are nominated by the BPP to act as liaisons between the sections and to pull together common threads of interest. They are available to give greater input into these working groups and play a role linking FIP with other professional organisations.
- Ms Diane Gal (Pharmabridge)
- Dr Lars-Ake Söderlund as Co-Chair of FIP Programme Committee
- FIP Young Pharmacists Group (YPG) Chair: Dr Carolyn Dewart
- International Pharmaceutical Students' Federation (IPSF) President: Ms Aya Jamal
The BPP meets twice yearly — in March/April and during the FIP annual congress — to discuss the various issues involving pharmacy practice and BPP initiatives.
What is a pharmacist?
In March 2016 the Board of Pharmaceutical Practice adopted the following definition of a "pharmacist":
A pharmacist is a scientifically-trained graduate healthcare professional who is an expert in all aspects of the supply and use of medicines. Pharmacists assure access to safe, cost-effective and quality medicines and their responsible use by individual patients and healthcare systems.
Responsible use of medicines implies that health-system stakeholder activities and capabilities are aligned to ensure that patients receive the right medicines at the right time, use them appropriately, and benefit from them. Bringing the right medicines to patients who need them requires the engagement of all actors, including governments, and a vision on how to integrate public and private interests and mobilise resources.